现在的位置: 首页时讯速递, 进展交流>正文
[JAMA Surg发表论文]:膈下出血患者院前挽救性主动脉血管内球囊部分封堵
2024年09月19日 时讯速递, 进展交流 [JAMA Surg发表论文]:膈下出血患者院前挽救性主动脉血管内球囊部分封堵已关闭评论

Original Investigation 

July 10, 2024

Prehospital Partial Resuscitative Endovascular Balloon Occlusion of the Aorta for Exsanguinating Subdiaphragmatic Hemorrhage

Robbie A. Lendrum, Zane Perkins, Max Marsden, et al

JAMA Surg. Published online July 10, 2024. doi:10.1001/jamasurg.2024.2254

Key Points

Question  Is it feasible to deploy prehospital zone 1 (supraceliac) partial resuscitative endovascular balloon occlusion of the aorta (Z1 P-REBOA) in the prehospital resuscitation of adult trauma patients at risk of cardiac arrest and death due to exsanguination?

Findings  In this cohort study of 16 patients with severe injuries and shock, prehospital Z1 P-REBOA was delivered successfully in 8 of the 11 patients who underwent Z1 REBOA. This strategy was associated with improved proximal blood pressure and early mortality.

Meaning  The findings indicate that in the prehospital resuscitation of adult trauma patients at risk of cardiac arrest and death due to exsanguination, Z1 P-REBOA is feasible and may enable early survival, but with a significant incidence of late death.

Abstract

Importance  Hemorrhage is the most common cause of preventable death after injury. Most deaths occur early, in the prehospital phase of care.

Objective  To establish whether prehospital zone 1 (supraceliac) partial resuscitative endovascular balloon occlusion of the aorta (Z1 P-REBOA) can be achieved in the resuscitation of adult trauma patients at risk of cardiac arrest and death due to exsanguination.

Design, Setting, and Participants  This was a prospective observational cohort study (Idea, Development, Exploration, Assessment and Long-term follow-up [IDEAL] 2A design) with recruitment from June 2020 to March 2022 and follow-up until discharge from hospital, death, or 90 days evaluating a physician-led and physician-delivered, urban prehospital trauma service in the Greater London area. Trauma patients aged 16 years and older with suspected exsanguinating subdiaphragmatic hemorrhage, recent or imminent hypovolemic traumatic cardiac arrest (TCA) were included. Those with unsurvivable injuries or who were pregnant were excluded. Of 2960 individuals attended by the service during the study period, 16 were included in the study.

Exposures  ZI REBOA or P-REBOA.

Main Outcomes and Measures  The main outcome was the proportion of patients in whom Z1 REBOA and Z1 P-REBOA were achieved. Clinical end points included systolic blood pressure (SBP) response to Z1 REBOA, mortality rate (1 hour, 3 hours, 24 hours, or 30 days postinjury), and survival to hospital discharge.

Results  Femoral arterial access for Z1 REBOA was attempted in 16 patients (median [range] age, 30 [17-76] years; 14 [81%] male; median [IQR] Injury Severity Score, 50 [39-57]). In 2 patients with successful arterial access, REBOA was not attempted due to improvement in clinical condition. In the other 14 patients (8 [57%] of whom were in traumatic cardiac arrest [TCA]), 11 successfully underwent cannulation and had aortic balloons inflated in Z1. The 3 individuals in whom cannulation was unsuccessful were in TCA (failure rate = 3/14 [21%]). Median (IQR) pre-REBOA SBP in the 11 individuals for whom cannulation was successful (5 [46%] in TCA) was 47 (33-52) mm Hg. Z1 REBOA plus P-REBOA was associated with a significant improvement in BP (median [IQR] SBP at emergency department arrival, 101 [77-107] mm Hg; 0 of 10 patients were in TCA at arrival). The median group-level improvement in SBP from the pre-REBOA value was 52 (95% CI, 42-77) mm Hg (P < .004). P-REBOA was feasible in 8 individuals (8/11 [73%]) and occurred spontaneously in 4 of these. The 1- and 3-hour postinjury mortality rate was 9% (1/11), 24-hour mortality was 27% (3/11), and 30-day mortality was 82% (9/11). Survival to hospital discharge was 18% (2/11). Both survivors underwent early Z1 P-REBOA.

Conclusions and Relevance  In this study, prehospital Z1 P-REBOA is feasible and may enable early survival, but with a significant incidence of late death.

Trial Registration  ClinicalTrials.gov Identifier: NCT04145271

抱歉!评论已关闭.

×
腾讯微博